Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions.

Lexicon is the only company to have systematically studied the role and function of thousands of genes, identifying more than 100 precise protein targets. This precision science enables us to pioneer the discovery of innovative, highly targeted medicines that treat serious, chronic conditions safely and effectively, and help patients live better, more empowered lives.

stock photo
Retrieving NASDAQ: LXRX

Company Presentation

Corporate Presentation

Annual Reports

annual report cover
annual report cover
annual report cover

Corporate Governance

Q3 September 30
Q2 June 30
Q1 March 31
10-K December 31
Q3 September 30
Q2 June 30
Q1 March 31
View all of our SEC Filings using EDGAR at www.sec.gov/edgar.

How to Contact Our Board of Directors

Our stockholders may contact our Board of Directors or any committee of our Board of Directors by sending written correspondence to the following address:

Lexicon Pharmaceuticals, Inc.
2445 Technology Forest Blvd, 11th Floor
The Woodlands, Texas 77381
Attn: Board of Directors (or name of committee)

How to Report Concerns Regarding Compliance Matters

Lexicon is committed to maintaining a culture of effective corporate compliance by promoting the open communication of concerns relating to compliance by Lexicon and its employees, officers and directors with applicable laws, regulations and Lexicon policies.

In order to encourage and facilitate the reporting of good faith concerns regarding Compliance Matters, Lexicon has established a confidential reporting helpline which may be used to report such concerns by means of telephone or website reporting:

Telephone: 833-222-7543
Website: https://lexpharma.ethicspoint.com/

Investor Inquiries:

Investor Relations

Media Inquiries:

Alina Cocuzza

See Our Latest News and Events

See Media Center
stock photo